Revolutionizing financing of pre-seed biotechs
We derisk drug discovery for early biotechs, enabling lead molecule discovery without institutional funding and increasing the pool of founders who will bring therapeutics to patients
The Problem
Pre-seed funding requirements prevent scientists from starting biotech companies
Founders today need significant capital before they have real data showing their drug idea works, but most investors can't bet millions on programs with little proof. So founders are stuck raising money too early for investors, and most fail to get their therapeutics funded. There’s no fast, affordable way for founders to create lead molecules and show their program is actually worth pursuing.
The Solution
Test 10,000x More Drug Candidates Before You Fundraise
BioGentic + DropXcell lets early-stage biotech founders screen thousands to millions of drug candidates quickly and affordably—before raising a big round. Instead of large upfront payments, we charge low fees and take milestones and royalties, so founders keep more equity. You get the data you need to prove your program works. We share in your success later.
Raise >$1M pre-seed
<5% companies funded
1 year to candidates
20 drugs quantified for function
Raise >$50k pre-seed
>50% companies funded
3 months to candidates
1M drugs quantified for function
After Leads
Raise >$1M
Pre-Clinical Development
Video: DropXCell's high-throughput screening technology
Starting out with just antibodies, but founders can reach out if interested in cell therapies, siRNA, peptides, protein-conjugates, enzymes, small molecules, or other modalities